大唐药业
(836433)
| 流通市值：13.75亿 | | | 总市值：20.81亿 |
| 流通股本：1.69亿 | | | 总股本：2.56亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 158,063,006.9 | 105,570,020.1 | 38,103,723.62 | 188,252,662.38 |
| 营业收入 | 158,063,006.9 | 105,570,020.1 | 38,103,723.62 | 188,252,662.38 |
| 二、营业总成本 | 144,641,833.1 | 98,567,111.55 | 36,896,109.7 | 183,583,530.59 |
| 营业成本 | 44,001,487.45 | 27,230,503.64 | 8,301,161.79 | 53,811,462.88 |
| 税金及附加 | 1,978,667.31 | 1,700,468.96 | 63,838.35 | 3,547,146.01 |
| 销售费用 | 64,189,993.11 | 49,847,319.88 | 20,717,841.19 | 92,488,721.6 |
| 管理费用 | 28,613,585.06 | 16,850,779.6 | 7,604,805.52 | 25,636,032.56 |
| 研发费用 | 6,429,607.81 | 3,738,021.21 | 1,238,549.82 | 7,072,545.71 |
| 财务费用 | -571,507.64 | -799,981.74 | -1,030,086.97 | 1,027,621.83 |
| 其中:利息费用 | 355,267.37 | 355,267.37 | -375,289.71 | 2,306,667.89 |
| 其中:利息收入 | 1,168,780.99 | 1,162,862.86 | 655,366.51 | 1,300,571.35 |
| 加:公允价值变动收益 | 123,995.34 | 123,995.34 | 102,578.82 | 663,716.94 |
| 加:投资收益 | 88,397.44 | 66,900.05 | 46,956.91 | 2,428,706.11 |
| 资产减值损失(新) | -1,649,734.38 | -844,663.33 | 167,601.38 | -1,501,307.84 |
| 信用减值损失(新) | -3,702,888.55 | -2,812,215.72 | -298,936.7 | -535,136.92 |
| 其他收益 | 3,942,157.5 | 2,140,100.53 | 351,587.59 | 3,606,148.86 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 12,223,101.15 | 5,677,025.42 | 1,577,401.92 | 9,331,258.94 |
| 加:营业外收入 | 518,501.08 | 518,501 | 94,501 | 1,816,457.3 |
| 减:营业外支出 | - | - | - | 511,295 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 12,741,602.23 | 6,195,526.42 | 1,671,902.92 | 10,636,421.24 |
| 减:所得税费用 | 2,364,797.08 | 1,054,613.07 | 439,229.16 | 2,708,784.79 |
| 六、净利润 | 10,376,805.15 | 5,140,913.35 | 1,232,673.76 | 7,927,636.45 |
| 持续经营净利润 | 10,376,805.15 | 5,140,913.35 | 1,232,673.76 | 7,927,636.45 |
| 归属于母公司股东的净利润 | 10,376,805.15 | 5,140,913.35 | 1,232,673.76 | 7,927,636.45 |
| (一)基本每股收益 | 0.04 | 0.02 | 0.01 | 0.03 |
| (二)稀释每股收益 | 0.04 | 0.02 | 0.01 | 0.03 |
| 九、综合收益总额 | 10,376,805.15 | 5,140,913.35 | 1,232,673.76 | 7,927,636.45 |
| 归属于母公司股东的综合收益总额 | 10,376,805.15 | 5,140,913.35 | 1,232,673.76 | 7,927,636.45 |
| 公告日期 | 2024-10-25 | 2024-08-14 | 2024-04-22 | 2024-03-20 |
| 审计意见(境内) | | | | 标准无保留意见 |